Status:
COMPLETED
Neurological and Neuropsychological Sequelae of COVID-19 Infection
Lead Sponsor:
Maastricht University
Collaborating Sponsors:
Netherlands Brain Foundation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
COVID-19 Infection
Eligibility:
All Genders
Brief Summary
COVID-19 is known to affect the respiratory system but may also have an impact on other organ systems, including the brain. A number of severely ill patients also presents neurological symptoms that m...
Detailed Description
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2). COVID-19 primarily affects the respiratory system. However, in sever...
Eligibility Criteria
Inclusion
- Patients:
- Objectified COVID-19 infection for which ICU or non-ICU hospital admission was necessary at one of the participating hospitals
- Age \> 18 years
- Sufficient command of the Dutch language to follow test instructions and understand questionnaires
- Informed consent.
- Family members (if present):
- Within the scope of this study, the term family member will be defined as a person who has good insight into the patient´s daily life functioning (before and after COVID-19 infection). This person can be the spouse, partner, adult child or, in some cases, another individual that plays the most significant role in the patient´s life. The patient will decide who this family member is. We will check the following criteria:
- Family member of a participant with COVID-19 infection as described above;
- Requires participation of the aforementioned family member as COVID-19 patient
- Age \> 18 years
- Sufficient command of the Dutch language to understand questionnaires
- Informed consent.
Exclusion
- Patients:
- objectified cognitive impairments before the hospital admission for the COVID-19 infection
- an unexpected incident leading to severe neurological damage occurring after hospital discharge (such as stroke or traumatic brain injury)
- contra-indications for MRI scanning (e.g. metal implants, cardiac pacemaker, claustrophobia, pregnancy).
- Family member: no exclusion criteria.
Key Trial Info
Start Date :
December 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 21 2022
Estimated Enrollment :
329 Patients enrolled
Trial Details
Trial ID
NCT04745611
Start Date
December 12 2020
End Date
February 21 2022
Last Update
May 2 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University
Maastricht, Limburg, Netherlands, 6229 ER
2
Amsterdam Universitair Medische Centra
Amsterdam, Netherlands
3
Universitair Medische Centra Utrecht
Utrecht, Netherlands